Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CERE-110: Adeno-Associated Virus Surgery · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CERE-110 | EXPERIMENTAL | CERE-110: Adeno-Associated Virus Delivery of NGF |
| Placebo | SHAM_COMPARATOR | Placebo Surgery |
| Name | Type | Description |
|---|---|---|
| CERE-110: Adeno-Associated Virus injection Surgery | DRUG | Injecting CERE-110 2.0 X 10\^11 vg into brain during surgical procedure. |
| Placebo Surgery | PROCEDURE | Placebo Surgery |
Inclusion Criteria: * Diagnosis of mild to moderate Alzheimer's disease * Approved medications for Alzheimer's disease may be taken if the dose has been stable for 3 months * A study partner who can attend all study visits * Good general health * Medically able to undergo neurosurgery Exclusion Cr...
Top 20 of 24 competitors
CERE-110 is an investigational gene therapy being studied for the treatment of mild to moderate Alzheimer's disease. It is administered via adeno-associated virus surgery, which involves delivering the therapy directly to the brain. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
CERE-110 is designed to deliver a gene that produces nerve growth factor, a protein that supports the survival and function of cholinergic neurons, which are affected in Alzheimer's disease. By providing this growth factor, the therapy aims to slow the degeneration of these neurons and potentially preserve cognitive function.
CERE-110 is being developed by Sangamo Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SGMO. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy for Alzheimer's disease.
CERE-110 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, sham-controlled study involving 49 participants with mild to moderate Alzheimer's disease. The drug remains investigational and is not yet approved for commercial use.
CERE-110 has been evaluated in a single completed Phase 2 clinical trial registered as NCT00876863. This study was a randomized, controlled trial conducted in the United States, enrolling 49 participants aged 55 years and older with mild to moderate Alzheimer's disease. The trial was double-blind and sham-controlled.
CERE-110 is an investigational gene therapy that is delivered through a surgical procedure involving adeno-associated virus. The term 'adeno-associated virus surgery' refers to the method of administration, not an alternative name for the drug itself. The therapy uses a viral vector to deliver the therapeutic gene to brain cells.